10378 studies found for:    NCI
Show Display Options
Rank Status Study
1 Active, not recruiting Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Conditions: Childhood Glioblastoma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligoastrocytoma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Gliosarcoma
Interventions: Drug: vorinostat;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: laboratory biomarker analysis
2 Completed Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: bevacizumab;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis
3 Completed Bryostatin and Vincristine in B-Cell Malignancies
Conditions: Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bryostatin 1;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis
4 Completed Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Intervention: Drug: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
5 Active, not recruiting Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Biological: cixutumumab;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
6 Terminated Saracatinib in Treating Patients With Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: saracatinib;   Other: hydrocortisone/placebo
7 Completed R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage IV Prostate Cancer
Interventions: Drug: R-(-)-gossypol acetic acid;   Drug: bicalutamide;   Other: laboratory biomarker analysis
8 Completed Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer
Conditions: Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage II Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions: Drug: erlotinib hydrochloride;   Drug: cisplatin;   Radiation: intensity-modulated radiation therapy;   Other: laboratory biomarker analysis
9 Completed
Has Results
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: alvocidib;   Drug: cytarabine;   Drug: mitoxantrone hydrochloride
10 Completed Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: sorafenib tosylate;   Drug: gemcitabine hydrochloride
11 Completed Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: cilengitide;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Terminated
Has Results
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Conditions: Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Intervention: Drug: sorafenib tosylate
13 Completed
Has Results
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: bortezomib
14 Completed Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
Condition: Recurrent Endometrial Carcinoma
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis
15 Unknown  Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
Conditions: Cardiac Toxicity;   Sarcoma
Interventions: Biological: filgrastim;   Drug: cisplatin;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
16 Active, not recruiting Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Condition: Malignant Neoplasm
Interventions: Drug: vismodegib;   Other: pharmacological study
17 Completed Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Conditions: Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: omacetaxine mepesuccinate;   Other: pharmacological study;   Other: laboratory biomarker analysis
18 Completed Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: atrasentan hydrochloride
19 Completed ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: fluorouracil;   Drug: gefitinib;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
20 Active, not recruiting RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: vismodegib;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: pharmacogenomic studies

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years